entertainment -WSS

entertainment

author：explore 2025-08-24 23:28:10 - browse：914

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Healthy food access boosts outcomes in two studies

entertainment

knowledge

WSS

Key House Republican on health care plans exit from Congress

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Doctors' information doesn't help them choose wisely when sick

Weight loss drugs should be covered by insurers, AMA says

Why did Pfizer dish out millions for a Super Bowl ad?

What is STAT's opinion section for?

Wikipedia

entertainment

focus

Guidelines to prevent youth baseball injuries need more muscle

Medical school prerequisites are outdated

Malaria cases in Florida and Texas: Here’s what you need to know

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

'Revelatory' study finds a smoking impact that remains after quitting

DIEP, the 'gold standard' of breast reconstruction, is under threat

Healthy food access boosts outcomes in two studies

focus

UnitedHealth sued over use of algorithm in Medicare Advantage plans

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Key House Republican on health care plans exit from Congress

A disappointing year of Humira biosimilars

Type 2 diabetes prevention programs work at large scale: study

explore

entertainment

knowledge

Wikipedia